Purpose: To describe the presenting features and functional outcomes in a series of patients with choroidal neovascular membrane complicating BEST1-related retinopathy (Best disease and autosomal recessive bestrophinopathy).
T he bestrophinopathies are a spectrum of inherited retinal dystrophies that result from mutation of the BEST1 gene. The commonest presentation within this group is Best disease (BD; Vitelliform Macular Dystrophy; OMIM 153700), a macular dystrophy characterized by bilateral accumulation of subretinal yellow material with later eruption into the photoreceptor layer and symptomatic reduction in vision. This form of the disease is most commonly associated with heterozygous missense mutations usually within the first half of the BEST1 gene. 1, 2 Best disease is almost always associated with a reduced light rise of the electrooculogram. 3 The full-field electroretinogram is normal. In contrast, autosomal recessive bestrophinopathy (ARB; OMIM 611809) associated with bi-allelic BEST1 variants results in a more widespread retinal disease with multifocal accumulation of subretinal deposit, and abnormalities of the full-field electroretinogram in addition to a reduced electrooculogram light rise. 4 In both BD and ARB, central visual acuity (VA) may be affected at any stage, although this usually is associated with either intraretinal fluid (IRF) accumulation, disruption of the photoreceptor layer during the vitelliruptive stage of dominant disease, or later atrophy. Rarely, visual decline may be the result of choroidal neovascular membrane (CNVM) formation. Although there are a few case reports and small series suggesting that CNVM can be successfully treated with intravitreal injections of recombinant antibodies directed against vascular endothelial growth factor (VEGF) (Ranibizumab, Bevacizumab), there is no evidence to suggest that outcomes are better than conservative management (observation alone). [5] [6] [7] [8] In this study, we report our clinical experience with a cohort of patients with BD and ARB, whose disease has been complicated by CNVM.
Methods
A retrospective review of the electronic patient record system at Moorfields Eye Hospital was performed with the search terms "Best disease," "recessive bestrophinopathy," "choroidal neovascularization," and "haemorrhage" covering the period between 2003 and 2015. The hospital notes were then reviewed both to confirm the diagnosis and document the clinical findings. Only patients with active CNVM were included. Choroidal neovascular membrane were deemed active if two of the following features were present -acute visual deterioration, retinal hemorrhage or exudate, IRF, irregular pigment epithelial detachment or evidence of neovascularization with fluorescein angiography. Presumed inactive, CNVM were diagnosed primarily on the basis of subretinal fibrosis and excluded from this study. Patient demographics (including sex and age at CNVM diagnosis) and symptoms were noted. Snellen VA recorded in the clinic was converted into a decimalized value for subsequent analysis. Retinal anatomy was documented with color fundus photography using a Topcon TRC 50IA retinal camera (Topcon Corporation, Tokyo, Japan) and optical coherence tomography (OCT) using the Spectralis spectral domain optical coherence tomography (SD-OCT) (Heidelberg Engineering, Heidelberg, Germany), with both line and volume scans available for interpretation. Fundus autofluorescence images were acquired using the autofluorescence mode of the Spectralis SD-OCT using either the 30 or 55°lenses. Fundus fluorescein angiography was performed using either the Topcon fundus camera or the Spectralis HRA systems.
To estimate the period prevalence of CNVM in BEST1-related eye disease, we reviewed retinal images of patients' known to harbor BEST1 mutations attending between 1.1.2010 and 1.1.2015. Only patients with active disease (as defined above) were included. Numerical data are described using median values and interquartile ranges, and compared using nonparametric analysis (Mann-Whitney U test).
This study was approved by the local research ethics committee, and all investigations were conducted in accordance with the principles of the Declaration of Helsinki.
Results

Cohort Demographics
Twelve patients were identified over the study period with a clinical diagnosis of either BD (n = 11) or ARB (n = 1) complicated by active CNVM. Molecular confirmation of the clinical diagnosis was available in 6/12 cases; genetic testing was not performed in two patients (Table 1) . For the molecularly unconfirmed cases, confidence in the clinical diagnosis was high because patients presented with at least two classical features of BD (macular phenotype, reduced electrooculogram, dominant family history). Six patients (50%) were male. Two patients had bilateral CNVM, thus data from 14 eyes of 12 patients were available for analysis. The follow-up period ranged from 0.8 to 6 years. One patient was diagnosed with BD as a child but only developed signs of CNVM aged 72 years (Patient 4). The median age at CNVM discovery was 15.5 years (interquartile range (IQR) 13 years). For the two patients with bilateral disease, sequential involvement of the fellow eye was observed within 4 years. Figure 1 shows images from the fellow eye of patient 8 to illustrate the natural history of BD uncomplicated by CNVM, for comparison with subsequent Figure  (Figures 2-5 ), which show illustrative images from Patients 2 and 9; salient features will be discussed in the Results and Discussion below.
Premorbid and Presenting Clinical Characteristics
For 11/14 eyes, the acuity before CNVM discovery was known and documented to be normal in 9/11 (median = 20/20, IQR = 0). For 3/14 eyes presented with active disease, consequently the previous acuity was unknown. For 2/11, the baseline VA was already reduced. Patient 4 presented aged 72 with advanced BD; her results will be presented separately. Patient 2 had suffered with previous neovascular disease in the same eye more than 2 years previously, accounting for her reduced presenting vision. Visual acuity in the fellow eye at the time of CNVM discovery was similar to the pre-CNVM acuity in affected eyes (median 20/20, IQR = 0), strongly suggesting that both eyes were at a similar stage of disease, and that neovascularization occurs relatively early in the disease course. The median VA at CNVM discovery was 20/60 (0.33, IQR = 0.17), overall representing a moderate reduction from baseline, although for individual patients this varied significantly (range = 20/20-20/400) ( Table 1 ). The presenting acuity did not seem to be inversely correlated with acuity in the fellow eye. Where SD-OCTs were available before CNVM detection (n = 9), preexisting subretinal fluid (SRF) was present in seven cases (example shown in Figure  2A ). Intraretinal fluid however was never observed. All patients reported a symptomatic reduction in their central vision (n = 14 eyes). In all cases, hemorrhage was noted at some point in the disease course, and was always subretinal in location and found either inside the boundaries of the yellow vitelliform lesion or at its border. Four patients presented in the month preceding hemorrhage detection with new symptoms of dysmorphopsia. In these cases, fundus fluorescein angiography showed no evidence of vascular leakage. It is however possible that they had active neovascular disease at this time that evaded detection with conventional imaging techniques.
Imaging in Active Disease
Fundus fluorescein angiography was requested in 9/ 14 cases and available for review. In a minority (3/9), late leakage of undetermined origin was evident. The majority (6/9) however demonstrated staining of the hyperfluorescent subretinal deposit, thus masking any subtle changes being further characterized. Indocyanine Optical coherence tomographic imaging of the retina-retinal pigment epithelium (RPE)-choroidal interface was available for all cases (14 eyes) and demonstrated abnormalities in the 4 cases that were symptomatic before hemorrhage being visualized. The earliest visible changes were at the level of the RPE, with separation from Bruch membrane due to presumed CNVM (see Figures 2B, 3B , 4E, 5A). The maximal site of RPE elevation was always found in the lower half of the macular lesion (n = 14), and often no disturbance was seen in the superior half (see Figure 3 , A and B). Other OCT features observed in patients with CNVM were SRF (n = 14), new IRF (n = 12), discontinuity in Bruch membrane (n = 7), areas of choroidal excavation (n = 4), and presumed photoreceptor outer segment delamination (n = 1). At the final follow-up visit, SRF was still present in all eyes.
Fundus autofluorescence imaging was used to identify subretinal deposition, which was hyperautofluorescent in all cases. Areas with SRF exhibited reduced autofluorescence, and when hemorrhage was present the normal autofluorescence was masked to a greater extent than by fluid alone. Inactive CNVM associated with fibrosis and organizing hemorrhage that had become depigmented may be mistaken for yellow subretinal deposit seen in typical BD. Autofluorescence was useful in differentiating deposit (hyperautofluorescent) from fibrosis and scarring, which are both hypoautofluorescent ( Figures 4B and 5 , D and E show autofluorescence images from the same eye before and after CNV development). Rupture of the RPE resulting from vertical extension of a CNVM was again associated with reduced autofluorescence. Image taken one year later shows greater irregularity of the ellipsoid line with some areas of focal hyperreflectivity in the outer nuclear layer. C. Further images taken one year later show approximation between retina and RPE close to the location of the previous hyperreflective areas, likely to be the area of subsequent scarring. At all time points, the RPE lies flat against Bruch membrane (itself not visible) with no signs of CNVM.
Outcomes
As all the patients identified presented with active CNVM after 2009, treatment with intravitreal bevacizumab (1.25 mg/0.05 mL) was potentially available to all cases. Seven eyes in this series received active treatment. Three of these patients had neovascular disease in their better seeing eye, as fellow eyes were affected by amblyopia (n = 2) or previous CNVM (n = 2); factors which may have influenced the decision to use an anti-VEGF agent. Most (5/7) of the treated patients were more than the age of 18, perhaps reflecting the ease of administering intravitreal therapy in an adult versus pediatric population where sedation or general anesthesia may be required. Of the 7 treated patients, 4 had a single injection, one received a second injection, one (Patient 12) had a predetermined course of three "loading" injections, and one (Patient 8) received 10 intravitreal treatments. The multiple injections required by Patient 8 may represent partial response to this therapy, membrane recurrence, or the inability to correctly identify an endpoint for treatment. Patient 2 was also thought to have developed late CNVM recurrence surrounding a previously inactive disciform scar.
As a group, the median change in vision after presenting with an active CNVM until the final followup visit was a gain of 0.34 decimalized Snellen lines (IQR 0.48), equivalent to a change from 20/60 (median presenting acuity) to 20/32. The treated eyes had a median gain in vision of 0.46 (IQR = 0.32), whereas eyes monitored by observation alone also gained vision, recording a more modest increase of 0.17 decimalized Snellen acuity (median gain, IQR = 0.39). This difference was found to be significant (Mann-Whitney U test, P , 0.05).
Central retinal thickening was evident in all cases at CNVM discovery, with a median central 1 mm macular thickness of 561 mm (IQR = 160) (observed) compared with 411 mm (IQR = 441) (treated) (MannWhitney U test, P . 0.05). At final follow-up, this had reduced to a similar extent in both the groups; 150 mm (IQR = 41) (observed) and 104 mm (IQR = 240) (treated) (Mann-Whitney U test, P . 0.05). A. Optical coherence tomography taken through the superior part of the lesion demonstrates subretinal fluid (between the RPE and the photoreceptor outer segments), cystic expansion of the outer nuclear layer (ONL), so that it merges with the outer plexiform layer (OPL), highlighting fluid probably accumulating between the ONL "proper" and the axonal component of this layer (Henle's layer), with the OPL band representing the dendritic connections between the photoreceptors and bipolar/horizontal cells. There is also microcystic edema within the inner nuclear layer. B. Scanning at a more inferior location identifies a focal hemorrhagic RPE elevation (arrow), blood within the subretinal space, and a small additional bright layer between the subretinal blood and the photoreceptor outer segments themselves immediately below the ellipsoid zone. C. Optical coherence tomography at a similar location 3 months later. The additional highly reflective layer is now absent. The subretinal space below now contains a broad zig-zag shaped line possibly consistent with delaminating photoreceptor outer segments. D. Eight months later, the ellipsoid layer is not clearly visible at this same location. E. Inferiorly, there is a hypertrophic outer retinal scar surrounded by the vitelliform detachment.
During a 5-year interval from 2010 to 2015, 107 molecularly confirmed cases of BEST1-related eye disease were recorded at Moorfields Eye Hospital. Molecular genetic testing is offered as an adjunct to the clinical examination, particularly if there is any clinical doubt regarding diagnosis. Testing would not have been offered, or accepted, in a further unquantifiable cohort of patients. Six of these patients later presented with active CNVM, suggesting a minimum prevalence of 5.6% (6/107) during this period.
Discussion
Choroidal neovascularization is thought to be a rare complication of BEST1-related retinopathy; however, the exact prevalence is currently unknown. [9] [10] [11] [12] [13] In this study, we have identified 14 eyes from 12 patients who have presented with active choroidal neovascular disease associated with either BD or ARB. Within our own genetic database, this equates to a period prevalence of 5.6%. In most of the cases, neovascularization occurred early in the disease course, when VA would otherwise be unaffected. The natural history of these membranes seems to follow a more benign course than those associated with age-related macular degeneration (ARMD), with a median gain of 0.34 decimalized units of Snellen acuity after resolution. Treatment with intraviteal bevacizumab (n = 7) was associated with greater visual gain when compared with observation alone (n = 7, Mann-Whitney U test P ,0.05). As the natural history of BD is for subretinal deposit to evolve to serous vitelliform detachment, the presence of subretinal fluid alone was not a useful guide to treatment.
Diagnosing CNVM in the context of BEST1-related retinopathy is complicated by the presence of preexisting subretinal deposit, which stains during fundus fluorescein angiography. We suggest additional features that may aid diagnosis or at least heighten clinical suspicion. Typical disease uncomplicated by neovascularization is associated with subretinal deposit that organizes over time, and often is later accompanied by SRF (Figure 1 ). The residual deposit becomes distributed in a pattern that is primarily influenced by gravity resulting in a predominantly inferior accumulation (the pseudohypopyon stage). Persistence of the dense deposit inferiorly may result in a greater insult to the inferior retina-RPE complex than that in the superior macula. In keeping with this hypothesis, whenever we were able to identify the neovascular complex, it was always located within the inferior half of the vitelliform lesion (Figures 2-5) . In no cases were membranes seen to arise from the superior half of the lesion. In most cases, the CNVM develop relatively early in the disease course, as normal acuity had been recorded within the past seven months in 82% (9/11 eyes), suggesting normal central photoreceptor function. As the membranes grow, they breach Bruch membrane and distort the RPE resulting in localized detachments ( Figures 2B, 3B, 4E, 5A ). In the absence of CNVM, the RPE should otherwise appear flat and apposed to Bruch membrane (Figure 1 ). Bruch membrane is usually not visible on OCT. Retinal pigment epithelium detachment results in the two structures now being separately resolved ( Figures 2B, 3B, 4E ), which are presumed to be the RPE and Bruch membrane. Type 1 membranes sit below the RPE and in the earliest stages are not perfused. 14 As they mature and support a blood flow they may leak, just as an occult CNVM associated with AMD would. Serous leakage into the sub-RPE compartment may result in fibrosis and RPE hyperplasia without the appearance of frank hemorrhage. 15 This may account for the fibrotic appearance of the macula in some patients with BD rather than the better defined atrophic maculopathy. If this is the case, CNVM may be a more common complication of BD because both atrophy and fibrosis were recognized as endpoints for this disease when it was originally classified. Should the CNVM breach the RPE becoming a Type 2 membrane, it can grow within the vitelliform space. 14 Contact with the subretinal surface provides a scaffold for progression, with or without duplication of the RPE. The membrane may bleed into the subretinal as well as sub RPE cavity or leak serous fluid. The presence of definitively new fluid would be hard to detect as SRF is a typical feature of BD in the absence of CNVM, but CNVM activity may additionally result in IRF, not typically seen in BD ( Figures 2C and 3A) but present in ARB ( Figure 6 ). As the CNVM contracts, it may exert tractional forces on the subretinal surface, and as there is sufficient space within the fluid-filled cavity we can occasionally observe a presumed detachment/delamination of the photoreceptor outer segments (present in Figure 3C ). Abnormal neovascular networks may also form anastomoses between the retinal and choroidal circulations (Type 3 membranes).
It is likely that a recently developed imaging technique, OCT angiography, will offer the best method of visualizing well-perfused CNVMs, because it is minimally influenced by the presence of subretinal deposit unlike fundus fluorescein angiography (personal observation, unpublished data). It will be interesting to see in these cases if CNVM anatomy as defined by OCT angiography correlates to visual outcome, because this may help to provide further prognostic information. If it becomes evident that specific subtypes of CNVM are associated with a better prognosis, or are more responsive to treatment, as is the case in ARMD, this additional information will be particularly helpful in the management of pediatric patients, where organizing treatment is not as straight forward as for adults. 15 Age-related CNVM are associated with diffuse thickening of the RPE basal membrane (basal laminar deposit) and secondary dystrophic calcification, whereas pediatric CNVM are not. 16 "Juvenile" membranes are thought to result from a more localized abnormality with a solitary site of subretinal vascular invasion rather than the multifocal vascular breaches that occur with age. 17 This is in keeping with the natural history and prognosis for these membranes being better than for those which occur in ARMD, and may explain why spontaneous regression is reported to be very common in pediatric CNVM. 18, 19 The initial report of visual outcomes in BD complicated by CNVM monitored by observation alone suggested that recovery could be expected in most of the cases (10/11 eyes in the initial series) with 9/11 eyes recording a final acuity of better than 20/50. 9 Smaller, more focal CNVM may also explain their sensitivity to treatment with anti-VEGF agents, because single treatments are often sufficient. [5] [6] [7] [8] 20 Rishi et al have most recently reported their experience treating pediatric CNVM and present data on four patients with BD who were followed up for more than one week. 21 The 3 patients who received treatment showed either an improvement (from 20/200-20/120 and 20/20) or stabilization of vision (at 20/30). One patient with inactive disease was followed by observation only and his vision spontaneously improved (20/200-20/ 30) , again highlighting the good visual outcome that may be seen with spontaneous regression of CNV in children. Pediatric CNVM may also complicate structural abnormalities (angioid streaks, choroidal osteoma, optic nerve head drusen, trauma, and less commonly myopia), intraocular inflammation (presumed ocular histoplasmosis syndrome, multifocal choroiditis, toxoplasmosis), or be idiopathic. 21 Choroidal neovascular membrane are also a rare complication of other childhood-onset forms of inherited retinal disease and have been reported to occur with choroideremia, 22 North Carolina macular dystrophy, 23 and Stargardt disease. 24 The visual outcomes presented, especially for the untreated group are perhaps surprisingly good, again highlighting the difference with ARMD. In two cases, only one treatment was required, suggesting that the membranes are exquisitely sensitive to anti-VEGF or that the disease is monophasic. Endpoints that are valid when treating CNVM associated with ARMD may not be helpful for membranes occurring in the context of BD. We suggest that as SRF can be expected to both predate and postdate CNVM discovery/activity, its usefulness as a biomarker for choroidal neovascularization is limited. Similarly, reliance on automated measurements of central retinal thickness from SD-OCTs may be unwise, because SRF will be overrepresented within this measurement. This may account for the difference in anatomical and functional outcomes that were recorded here, because patients with typical CNVM recorded better visual outcomes if they received treatment (P = 0.03), however, their central retinal thickness measurements did not mirror these changes. A more accurate use of SD-OCT data may involve segmentation of the retinal sublayers, recording measurements between the internal limiting membrane and ellipsoid zone, perhaps more representative of IRF. This parameter may correlate better with changes in vision, although our experience of treating patients with ARMD may suggest that this will not always be the case. For ARB, even this technique may have limited utility, as IRF is the norm. Intraretinal fluid may also be seen in a minority of cases of end-stage BD, so in the setting of significant RPE disease both SRF and IRF may be expected, even in the absence of CNVM, thereby complicating diagnosis.
Surprisingly in one case, hemorrhage secondary to the neovascular membrane did not occur until after the age of 70, whereas all other cases were detected under the age of 25 years of age. A number of explanations are possible. First, CNVM occurrence may be independent of disease stage, although in this series, 9/14 eyes recorded a normal acuity within the past seven months, suggesting that most of the photoreceptors were unaffected consistent with the earliest stages of disease. Second, this patient may have suffered with previous neovascular complications, and the detected episode in fact represents a recurrence of disease activity. Finally, the CNVM identified might have occurred independent of the BEST1 mutation, relating instead to ARMD. As monogenic disorders can show phenotypic overlap with ARMD, and mutations in BEST1 may be nonpenetrant and variably expressed, it is also quite possible that BEST1-related retinopathy may masquerade as either neovascular or nonneovascular ARMD.
Finally, it is important to highlight that the retrospective nature of this study carries with it inherent limitations. Underascertainment is likely to have occurred, most evident because of the lack of cases identified before 2009. Molecular confirmation of the diagnosis was not available for 8/14 cases, although all did report a dominant family history consistent with BD, and in two cases, a reduced Arden ratio was additionally recorded. Absence of randomization when selecting the intervention may have provided a bias toward treating the more severe cases, although by chance the presenting visual acuities seem to be well matched between the 2 groups (median = 0.32 versus 0.34, decimalized Snellen). Visual acuity data may also have been influenced by uncorrected refractive error which was not controlled for, but perhaps equally distributed throughout the two groups. Finally, the wide variation in duration of follow-up may influence the final acuity, as the natural history of BD is progression to macular atrophy. No such trend was apparent however.
In summary, we present the largest case series to date of CNVM complicating BD and ARB. In this nonrandomized retrospective series, we have identified that these membranes have a high rate of spontaneous resolution, and additional visual gains may be obtained using intravitreal anti-VEGF therapy. In the vast majority of cases, CNVM should be considered as a relatively early potential complication of BD. Occasionally, this rare complication may recur. We also highlight novel OCT features seen in both early and late neovascular disease that will facilitate identification of these lesions. Finally, we suggest that CNVM may be a potentially underrecognized complication of BEST1-related retinopathy, and the advent of novel imaging techniques may help to prove this.
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